• Eun-Su Choi, Jiyoun Lee, Ji Hyeon Lee, Jin-Hee Kim, Sung-Hee Han, and Jin-Woo Park.
• Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Gyeonggi-do, South Korea.
• J Clin Anesth. 2024 Nov 1; 98: 111588111588.

Study ObjectiveTo compare the effects of neostigmine/glycopyrrolate (a traditional agent) and sugammadex on bowel motility recovery and the occurrence of digestive system complications after colorectal surgery.DesignProspective, randomized controlled trial.SettingA single tertiary center.Patients111 patients undergoing laparoscopic colorectal surgery.InterventionsPatients were randomized into two groups based on the block reversal agent: 1) a mixture of 50 μg.kg-1 of neostigmine and 10 μg.kg-1 of glycopyrrolate (neostigmine group) and 2) 2 mg.kg-1 of sugammadex (sugammadex group).MeasurementsThe primary outcome was the time from the surgery's completion to the first flatus. The time to the first postoperative defecation, incidences of postoperative nausea or vomiting, ileus, and dry mouth, as well as postoperative length of stay, were also assessed.Main ResultsThe time to the first flatus was significantly shorter in the sugammadex group than in the neostigmine group (59 [42-79] h vs 69 [53-90] h, P = 0.027). The time to the first defecation and the incidences of postoperative nausea or vomiting and ileus did not differ between the groups, nor did the postoperative length of stay. However, the incidence of postoperative dry mouth was significantly lower in the sugammadex group than in the neostigmine group (7 patients [13%] vs 39 patients [71%], P < 0.001).ConclusionsThe time to the first flatus was shorter using 2 mg.kg-1 sugammadex to reverse the neuromuscular block for laparoscopic colorectal surgery compared to reversal with conventional neostigmine/glycopyrrolate.Copyright © 2024 Elsevier Inc. All rights reserved.

41 keywords...

hide…